Non-Interventional Study With Vinorelbine ORAL in Advanced Non-Small Cell Lung Carcinoma(NSCLC) and Metastatic Breast Cancer (MBC)

Pierre Fabre

Status: Completed

Conditions: Non Small Cell Lung Carcinoma; Metastatic Breast Cancer

Study type: Observational

Funder types: Industry

Identifiers

NCT00890903

IOM-155

Details and patient eligibility

About

The purpose of this non-interventional study is to collect data on efficacy and toxicity of the use of Navelbine ORAL in daily routine in Germany (especially after availability of an 80mg capsule). The study focusses on concomitant antiemetic therapy and patient compliance.

Enrollment: 62 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• At least 18 years old
• Male and female patients
• Advanced NSCLC (Stage III or IV) or Antracycline-resistant MBC
• Therapy with Navelbine capsules in any palliative treatment line
• Signed patient informed consent

Exclusion criteria

• Pregnancy and nursing
• All other exclusion criteria listed in SPC (summary of product characteristics)
• lack of signed Patient informed consent

Trial design

62 participants in 2 patient groups

NSCLC

Description:

Patients with advanced non-small cell lung cancer

MBC

Description:

Female patients with metastatic, Anthracycline-resistent breast cancer